PMID- 21861141
OWN - NLM
STAT- MEDLINE
DCOM- 20120209
LR  - 20211020
IS  - 1435-5922 (Electronic)
IS  - 0944-1174 (Linking)
VI  - 46
IP  - 11
DP  - 2011 Nov
TI  - Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant 
      patients with gastroesophageal reflux disease and the dose escalation challenge 
      of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related 
      Symptom Research Group in Japan.
PG  - 1273-83
LID - 10.1007/s00535-011-0446-2 [doi]
AB  - BACKGROUNDS: Some non-erosive reflux disease (NERD) and reflux esophagitis (RE) 
      patients are unresponsive to a proton pump inhibitor (PPI) at standard dose. We 
      investigated the predictive marker of the efficacy of PPI for GERD patients 
      including NERD and RE treated with standard and increased doses of a PPI. 
      METHODS: Patients with symptomatic gastroesophageal reflux disease (GERD) (NERD 
      and RE) were treated with rabeprazole (RPZ) 10 mg once daily for 4 weeks. The RPZ 
      dosage was increased to 10 mg twice daily for an additional 2 weeks and again to 
      20 mg twice daily for another 2 weeks if heartburn was not relieved. Baseline 
      characteristics and efficacy of RPZ were assessed on the basis of a heartburn 
      diary and frequency scale for symptoms of GERD (FSSG). RESULTS: Complete 
      heartburn relief rates after 4 weeks were 42.5% (31/73) and 67.9% (19/28) in NERD 
      and RE groups, respectively, which rose to 68.9 and 91.7% after dose escalation. 
      Multivariate analysis revealed that parameters associated with resistance to RPZ 
      10 mg once daily were female, non-smoking, frequent heartburn, low score for 
      question 4 (Q4) of the FSSG (subconsciously rubbing the chest), and high scores 
      for Q3 (heavy stomach after meal) and Q7 (unusual sensation in the throat). 
      Frequent heartburn and a high score for Q7 were associated with resistance to RPZ 
      20 mg twice daily. FSSG scores of patients resistant to RPZ were significantly 
      higher in comparison with responders before and during treatment. CONCLUSIONS: 
      FSSG could predict response to a PPI for symptomatic GERD. Increase of RPZ dose 
      is useful for treatment of GERD refractory to the standard dose of RPZ.
FAU - Furuta, Takahisa
AU  - Furuta T
AD  - Center for Clinical Research, Hamamatsu University School of Medicine, 1-20-1 
      Handayama, Higashi-ku, Hamamatsu 431-3192, Japan. furuta@hama-med.ac.jp
FAU - Shimatani, Tomohiko
AU  - Shimatani T
FAU - Sugimoto, Mitsushige
AU  - Sugimoto M
FAU - Ishihara, Shunji
AU  - Ishihara S
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
FAU - Kusano, Motoyasu
AU  - Kusano M
FAU - Koike, Tomoyuki
AU  - Koike T
FAU - Hongo, Michio
AU  - Hongo M
FAU - Chiba, Tsutomu
AU  - Chiba T
FAU - Kinoshita, Yoshikazu
AU  - Kinoshita Y
CN  - Acid-Related Symptom Research Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20110824
PL  - Japan
TA  - J Gastroenterol
JT  - Journal of gastroenterology
JID - 9430794
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*administration & dosage
MH  - Adult
MH  - Anti-Ulcer Agents/administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - *Drug Resistance
MH  - Esophagitis, Peptic/complications/*drug therapy
MH  - Female
MH  - Gastroesophageal Reflux/complications/*drug therapy
MH  - Heartburn/etiology/*prevention & control
MH  - Humans
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Rabeprazole
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
FIR - Ohara, Shuichi
IR  - Ohara S
FIR - Shimoyama, Yasuyuki
IR  - Shimoyama Y
FIR - Kawamura, Osamu
IR  - Kawamura O
FIR - Hoshihara, Yoshio
IR  - Hoshihara Y
FIR - Yakabi, Kouji
IR  - Yakabi K
FIR - Kurosawa, Susumu
IR  - Kurosawa S
FIR - Watanabe, Yusuke
IR  - Watanabe Y
FIR - Nishino, Masafumi
IR  - Nishino M
FIR - Joh, Takashi
IR  - Joh T
FIR - Sasaki, Makoto
IR  - Sasaki M
FIR - Wada, Tsuneya
IR  - Wada T
FIR - Higuchi, Kazuhide
IR  - Higuchi K
FIR - Habu, Yasuki
IR  - Habu Y
FIR - Miwa, Hiroto
IR  - Miwa H
FIR - Oshima, Tadayuki
IR  - Oshima T
FIR - Tanaka, Junji
IR  - Tanaka J
FIR - Haruma, Ken
IR  - Haruma K
FIR - Manabe, Noriaki
IR  - Manabe N
FIR - Adachi, Kyoichi
IR  - Adachi K
FIR - Furuta, Kenji
IR  - Furuta K
FIR - Ito, Masanori
IR  - Ito M
FIR - Fujimoto, Kazuma
IR  - Fujimoto K
EDAT- 2011/08/24 06:00
MHDA- 2012/02/10 06:00
CRDT- 2011/08/24 06:00
PHST- 2011/04/24 00:00 [received]
PHST- 2011/06/28 00:00 [accepted]
PHST- 2011/08/24 06:00 [entrez]
PHST- 2011/08/24 06:00 [pubmed]
PHST- 2012/02/10 06:00 [medline]
AID - 10.1007/s00535-011-0446-2 [doi]
PST - ppublish
SO  - J Gastroenterol. 2011 Nov;46(11):1273-83. doi: 10.1007/s00535-011-0446-2. Epub 
      2011 Aug 24.